Phase I/II study of a fine-powder formulation of cisplatin for transcatheter arterial chemoembolization in hepatocellular carcinoma

Hepatology Research

Volumn 40, Issue 4, 2010, Pages 369-375

  Moriguchi, Masamichi ^a   Takayama, Tadatoshi ^a   Nakamura, Masahiko ^a   Aramaki, Osamu ^a   Higaki, Tokio ^a   Nakayama, Hisashi ^a   Ohkubo, Takao ^a   Fujii, Masashi ^a  

^a NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cisplatin; Hepatocellular carcinoma; Transcatheter arterial chemoembolization

Indexed keywords

CISPLATIN; GELATIN; GELPART; IODINATED POPPYSEED OIL; ULTRA FLUIDE; UNCLASSIFIED DRUG;

ADULT; AGED; ANOREXIA; ARTICLE; BILIRUBIN BLOOD LEVEL; CHEMOEMBOLIZATION; CHEMOTHERAPY INDUCED EMESIS; CHOLANGITIS; CHOLECYSTITIS; CLINICAL ARTICLE; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYPERBILIRUBINEMIA; KIDNEY FAILURE; LEUKOPENIA; LIVER ABSCESS; LIVER CELL CARCINOMA; MALE; NAUSEA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT RESPONSE;

EID: 77953208767     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2009.00606.x     Document Type: Article

References (13)

1. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003, 37:429-42.
2. Ueno K, Miyazono N, Inoue H, Nishida H, Kanetsuki I, Nakajo M. Transcatheter arterial chemoembolization therapy using iodized oil for patients with unresectable hepatocellular carcinoma: evaluation of three kinds of regimens and analysis of prognostic factors. Cancer 2000, 88:1574-81.
3. Ono Y, Yoshimasu T, Ashikaga R. Long-term results of lipiodol-transcatheter arterial embolization with cisplatin or doxorubicin for unresectable hepatocellular carcinoma. Am J Clin Oncol 2000, 23:564-68.
4. Kamada K, Nakanishi T, Kitamoto M. Long-term prognosis of patients undergoing transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: comparison of cisplatin lipiodol suspension and doxorubicin hydrochloride emulsion. J Vasc Interv Radiol 2001, 12:847-54.
5. Kawai S, Tani M, Okamura J. Prospective and randomized trial of lipiodol-transcatheter arterial chemoembolization for treatment of hepatocellular carcinoma: a comparison of epirubicin and doxorubicin (second cooperative study). Semin Oncol 1997, 24(6):S6-38-S6-45. Suppl
6. Achenbach T, Seifert JK, Pitton MB, Schunk K, Junginger T. Chemoembolization for primary liver cancer. Eur J Surg Oncol 2002, 28:37-41.
7. Ikeda M, Maeda S, Shibata J. Transcatheter arterial chemotherapy with and without embolization in patients with hepatocellular carcinoma. Oncology 2004, 66:24-31.
8. A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. N Engl J Med 1995, 332:1256-61. Groupe d'Etude et de traitment du carcinoma hepatocellulaire
9. Yoshikawa M, Ono N, Yodono H, Ichida T, Nakamura H. Phase II study of hepatic arterial infusion of a fine-powder formulation of cisplatin for advanced hepatocellular carcinoma. Hepatology Res 2008, 38:474-83.
10. Therasse P, Arbuck SG, Eisenhauer EA. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000, 92:205-16.
11. Go RS, Adjei AA. Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. J Clin Oncol 1999, 17:409-22.
12. Yamashita YI, Taketomi A, Itoh S. Phase I/II study of the lipiodolization using DDP-H (CDDP powder; IA-call®) in patients with unresectable hepatocellular carcinoma. Cancer Chemother Pharmacol 2010, 65:301-7.
13. Court WS, Order SE, Siegel JA. Remission and survival following monthly intraarterial cisplatinum in nonresectable hepatoma. Cancer Invest 2002, 20:613-25.